Infections following hematopoietic stem cell transplantation

Infectious Disease Clinics of North America

Volumn 15, Issue 2, 2001, Pages 483-520

  Leather, Helen L ^a   Wingard, John R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIDOFOVIR; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ETHAMBUTOL; FLUCONAZOLE; IMIPENEM; ISONIAZID; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; RIBAVIRIN; RIFAMPICIN; TOBRAMYCIN; VALACICLOVIR; VANCOMYCIN; VIDARABINE;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS; HUMAN; INFECTION; MYCOSIS; OPPORTUNISTIC INFECTION; PARAINFLUENZA VIRUS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 0034963946     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70157-4     Document Type: Article

References (224)

1. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation
2. Prophylaxis: A strategy to minimize resistance
3. Abelcet (Amphotericin B lipid complex) versus amphotericin B for treatment of invasive candidiasis: A prospective, randomized multicenter trial
4. Human herpes virus-6 infection in marrow graft recipients: Role in pathogenesis of graft-versus-host disease
5. Early gram-positive bacteremia in BMT recipients: Impact of three different approaches to antimicrobial prophylaxis
6. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia
7. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: A prospective, randomized trial
8. Single ganciclovir daily dose as CMV preemptive treatment after BMT. A pilot study
9. Successful treatment of cytomegalovirus pneumonitis after allogeneic bone marrow transplantation using high titer CMV immunoglobulin (Cytotect)
10. Fungal infections in cancer patients: An international autopsy survey
11. Infections in cancer patients
12. Phase I evaluation of a RSV-specific humanized monoclonal antibody (MEDI-493) after hematopoietic stem cell transplantation (HSCT)
13. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation
14. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
15. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
16. Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is because of a lack of CMC-specific T-cell responses
17. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation
18. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
19. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults
20. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemia regimen
21. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity
22. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia: The trade-off for reduced gram-negative sepsis
23. A double-blind, randomized controlled trial of amphocil (ABCD) versus amphotericin B (AmB) for the treatment of invasive aspergillosis in immunocompromised patients
24. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
25. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
26. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience
27. Blood and marrow transplantation
28. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation
29. Adenovirus infections in patients undergoing bone marrow transplantation
30. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infection
31. CDC/IDSA/ASBMT guidelines for the prevention of opportunistic infections (OIs) in hematopoietic stem cell transplantation (HSCT) recipients
32. Listeriosis in bone marrow transplant recipients: Incidence, clinical features and treatment
33. Epstein-Barr virus infection in renal transplant recipients: Effects of antithymocyte globulin and interferon
34. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir
35. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis
36. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
37. Human herpesvirus-6 infections after bone marrow transplantation: Clinical and virologic manifestations
38. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
39. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis
40. Treatment of cytomegalovirus pneumonia
41. B-cell lymphoproliferative disorders after bone marrow transplant: An analysis of ten cases with emphasis on Epstein-Barr virus detection in-situ hybridization
42. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population
43. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute non-lymphocytic leukaemia
44. Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin
45. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis
46. Treatment of invasive aspergillosis with itraconazole
47. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients
48. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - A compassionate use experience
49. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients
50. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
51. Late onset cytomegalovirus disease after allogeneic stem-cell transplantation
52. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique
53. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for the treatment of invasive aspergillosis
54. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
55. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: A 5-year prospective study
56. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis
57. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients
58. Respiratory syncyctial virus infection in immunocompromised adults
59. Herpes simplex virus resistant to acyclovir: A study in a tertiary care center
60. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy
61. Gram-positive bacteremia in granulocytopenic cancer patients
62. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer: A trial of oral penicillin V or placebo combined with perfloxacin
63. Cytomegalovirus pneumonia: The use of ganciclovir in marrow transplant recipients
64. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
65. Treatment of infection caused by Pneumocystis carinii
66. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem-cell transplantation or intensive chemotherapy for haematological disorders
67. Oral antimicrobial prophylaxis in bone marrow transplant recipients: Randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin
68. The effect of the new triazole, voriconazole (UK-109,496) on the interactions of Candida albicans and Candida krusei with endothelial cells
69. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
70. Late CMV disease in marrow transplantation is predicted by virus load in plasma
71. Nontuberculosis mycobacterial infections in hematopoietic stem-cell transplant recipients: Characteristics of respiratory and catheter-related infections
72. Prolonged granulocytopenia: The major risk factor for invasive fungal pulmonary aspergillosis in patients with acute leukemia
73. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA infection program
74. Definition of a minimal effective trough concentration of itraconazole for antifungal prophylaxis in severely neutropenic patients with haematological malignancies
75. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial
76. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
77. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
78. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
79. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematological malignancies
80. Prevention of viridans-group streptococcal septicemia in oncohematologic patients: A controlled comparative study on the effect of penicillin G and cotrimoxazole
81. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients
82. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications
83. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B
84. An outbreak of respiratory syncyctial virus in a bone marrow transplant center
85. Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia
86. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
87. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants
88. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: Can strain differences compensate for loss of thymidine kinase in pathogenesis?
89. Recommendations for preventing the spread of vancomycin resistance
90. Adenovirus infections in hematopoietic stem cell transplant recipients
91. Mycobacterial infections in bone marrow transplant recipients
92. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: Infectious Diseases Society of America
93. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children
94. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients
95. High dose intravenous ciprofloxacin in febrile neutropenic patients
96. Adenovirus-associated haemorrhagic cystitis after bone marrow transplantation successfully treated with intravenous ribavirin
97. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation
98. Empiric use of vancomycin during prolonged treatment induced granulocytopenia: Randomized, double-blind placebo controlled clinical trial in patients with acute leukemia
99. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: A randomized, double-blind, placebo controlled trial
100. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome
101. An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit
102. Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation
103. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients
104. A randomized prospective study of imipenemcilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients
105. Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: Role of severe neutropenia and mucositis
106. Benefit of prophylaxis by intravenous systemic vancomycin in granulocytopenic patients: A prospective, randomized trial among 59 patients
107. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation
108. Evolution, incidence and susceptibility of bacterial isolates from 519 BMT patients at a university hospital
109. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
110. Protected environments and prophylactic antibiotics: A prospective controlled study of their utility in the therapy of acute leukemia
111. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial
112. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation
113. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with hematological malignancies
114. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
115. Cidofovir for treatment of CMV and adenovirus infections in allogeneic stem cell transplant recipients
116. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
117. Cytomegalovirus infection after marrow transplantation for aplastic anemia
118. Infection with varicella-zoster virus after marrow transplantation
119. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation
120. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
121. Respiratory syncytial virus infections in adult bone marrow transplant recipients
122. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody
123. Listeriosis in bone marrow transplant recipients
124. Bacteremia caused by glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors
125. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
126. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies
127. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
128. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation
129. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors
130. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant
131. Nonbacterial pneumonia after allogeneic transplantation: A review of ten years' experience
132. Risk factors for cytomegalovirus infection after human marrow transplantation
133. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia
134. Infection in bone marrow transplant recipients
135. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-vs-host disease
136. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies
137. Bacteremia caused by Stenotrophomonas (Xanthomonas) maltophilia: A prospective, multicenter study of 91 episodes
138. Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin
139. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - Is it justified?
140. Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients
141. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer
142. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
143. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
144. Treatment of lymphoproliferative disease with rituximab
145. Listeriosis in bone marrow transplant recipients
146. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients
147. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients
148. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients
149. A randomized trial of cefepime versus ceftazidime as initial therapy for patients with prolonged fever and neutropenia after intensive chemotherapy
150. Late infections after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients
151. The changing pattern of infection in neutropenic patients
152. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
153. Stenotrophomonas (Xanthomonas) maltophilia: A multidrug-resistant nosocomial pathogen
154. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients
155. Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci
156. International surveillance of bloodstream infections caused by Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
157. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
158. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
159. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
160. Optimization of itraconazole therapy using target drug concentrations
161. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
162. Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow transplant recipients
163. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study
164. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient
165. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients
166. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
167. Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlations data for fluconazole, itraconazole, and Candida infections
168. Management of fever of unknown origin in patients with neoplasms and neutropenia
169. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis
170. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
171. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation
172. Mycobacterial infections following bone marrow transplantation: A 20 year retrospective review
173. Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin
174. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis
175. Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients: A randomized, double-blind placebo-controlled study
176. Acyclovir prophylaxis of herpes-simplex virus infections: A randomized, double-blind, controlled trial in bone-marrow transplant recipients
177. Abdominal presentation of varicellazoster infection in recipients of allogeneic bone marrow transplanation
178. Infection prevention during profound granulocytopenia: New approaches to alimentary canal microbial suppression
179. Norfloxacin for the prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation
180. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group
181. Herpes zoster infection after autologous bone marrow transplantation
182. Adenovirus infections in patients undergoing bone marrow transplantation
183. Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar fluid
184. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
185. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis
186. Randomized study of growth factors postperipheral blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit
187. Epstein-Barr virus infections: Biology, pathogenesis and management
188. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria
189. Itraconazole in cyclodextrin solution
190. Oral nonabsorbed antibiotics prevent infection in acute nonlymphoblastic leukemia
191. Nocardiosis after bone marrow transplantation: A retrospective review
192. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia
193. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
194. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir
195. Once daily intravenous gancyclovir (ODG) as preemptive therapy (PT) for cytomegalovirus (CMV) viremia in 200 patients undergoing allogeneic related donor peripheral blood stem cell transplantation (allo-PBSC) and matched unrelated donor bone marrow transplantation (MUD-BMT)
196. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir
197. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
198. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: Does it have clinical significance?
199. Mycobacterial central venous catheter tunnel infection: A difficult problem
200. Interstitial pneumonitis after bone marrow transplantation: Assessment of risk factors
201. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients
202. Infections in adults undergoing unrelated donor bone marrow transplantation
203. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation
204. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
205. The management of CMV infections after bone marrow transplantation: A shift in paradigm
206. Interstitial pneumonitis after allogeneic bone marrow transplantation: Nine year experience at a single institution
207. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
208. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
209. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy
210. Interstitial pneumonitis following bone marrow transplantation
211. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
212. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses
213. Importance of Candida species other than C. albicans as pathogens in oncology patients
214. Advances in the management of infectious complications after bone marrow transplantation
215. Fungal infections after bone marrow transplant
216. Opportunistic infections after blood and marrow transplantation
217. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone-marrow transplant recipients: Results of a placebo-controlled, double-blind trial
218. Cytomegalovirus infections after allogeneic bone marrow transplantation
219. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients
220. Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group
221. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: Importance of empiric therapy with acyclovir
222. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
223. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma
224. Epstein-Barr virus lymphoproliferation after bone marrow transplantation: Incidence, risk factors and complications